0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover3943.37%IV39.69%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.0717Delta0.0206Gamma66.32Leverage Ratio-11.8750Theta0.0000Rho-4.75Eff Leverage0.0002Vega
Grail Stock Discussion
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet